House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Oncology

Non-muscle-invasive bladder cancer

EAU · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

The 2026 EAU NMIBC guideline combines complete TURBT and reliable pathology with risk-based intravesical therapy, timely cystectomy discussion and long-term surveillance. Accurate BCG-exposure and failure definitions are crucial. The update also addresses checkpoint-inhibitor additions to maintenance BCG in selected BCG-naive high-risk patients, with explicit benefit–toxicity discussion.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Establish stage and obtain adequate tissue

  • Assess haematuria and urinary symptoms with renal/bladder ultrasound and/or CT urography. Suspected bladder cancer requires cystoscopy with or without biopsy; cytology or another noninvasive test cannot replace it. [1]
  • Use voided urine cytology alongside cystoscopy to detect high-grade disease. If local-staging MRI is used, obtain it before transurethral bladder-tumour resection. [1]
  • Perform TURBT with pathology as the initial diagnostic and therapeutic step. Document tumour location, appearance, size, multiplicity, extent and completeness of resection, complications, and the specimens submitted. [1]
  • Pathology should specify grade, stage, lymphovascular invasion, urothelial subtype, carcinoma in situ and detrusor muscle. Repeat TURBT after incomplete or uncertain resection, for T1 disease, or when detrusor muscle is absent except in Ta low-grade/G1 tumours or primary CIS. [1]
  • When repeat TURBT is indicated, EAU suggests performing it within two–six weeks and including the original tumour site. Positive cytology with negative cystoscopy requires assessment for upper-tract cancer, occult bladder CIS and prostatic-urethral tumour. [1]

Match risk prediction to the treatment population

  • Classify NMIBC into the four EAU progression-risk groups. Choose the recurrence or progression model according to prior BCG exposure rather than applying one calculator indiscriminately. [1]
  • For BCG-treated patients, use the relevant 2016 EORTC or CUETO model: the former corresponds to one–three years of maintenance and CUETO to five–six months. Counsel smokers to stop and discuss high/very-high-risk cases in a multidisciplinary board where possible. [1]

Choose adjuvant therapy by recurrence and progression risk

  • For low-risk disease and small presumed low-grade papillary recurrence more than a year after TURBT, offer a single immediate intravesical chemotherapy instillation. If given, administer within 24 hours; omit it for suspected or overt perforation or bleeding requiring irrigation. [1]
  • Offer postoperative saline or water continuous irrigation when a single chemotherapy instillation cannot be given. Small recurrent low-grade Ta lesions can be treated by office fulguration; active surveillance or chemoablation is a weaker alternative for selected presumed low-grade disease. [1]
  • For intermediate-risk disease, intravesical chemotherapy is generally a reasonable first choice; one year of full-dose BCG with maintenance is an alternative. Base the decision on recurrence/progression risk, benefit and adverse effects. [1]
  • For high-risk disease, offer full-dose BCG for one–three years and discuss immediate radical cystectomy. Balance added maintenance benefit in years two and three against toxicity, costs and BCG access. [1]
  • For very-high-risk disease, discuss immediate radical cystectomy. Full-dose BCG for one–three years remains an option for selected patients, especially those declining or unfit for cystectomy. [1]
  • In carefully selected, informed BCG-naive high- or very-high-risk patients, discuss the benefits and harms of adding sasanlimab or durvalumab to BCG with maintenance. Treat these as separate options; immature long-term data and immune toxicity require caution and shared decisions. [1]

Observe BCG exclusions and distinguish true unresponsiveness

  • Do not instil BCG during the first two weeks after TURBT, with visible haematuria, after traumatic catheterisation or with symptomatic urinary infection. These are absolute contraindications in the guideline. [1]
  • BCG-unresponsive disease includes refractory tumours and high-grade Ta/T1 recurrence within six months or CIS within 12 months after adequate BCG. Adequate exposure means at least five of six induction doses plus at least two of six repeat-induction doses or two of three maintenance doses. [1]
  • Offer radical cystectomy for BCG-unresponsive tumours rather than assuming further BCG will work. Low-grade recurrence during or after BCG is not classified as BCG failure. [1]
  • For BCG-unresponsive patients who decline cystectomy or are unsuitable because of comorbidity, consider bladder-preserving strategies, preferably in trials. Options include intravesical chemotherapy, device-assisted approaches and selected immunotherapies; eligibility is treatment-specific. [1]

Continue risk-adapted surveillance

  • Base follow-up on cystoscopy. For low-risk Ta disease, EAU suggests cystoscopy at three months, then nine months later if negative, and yearly for five years. [1]
  • For intermediate-risk low-grade Ta disease, consider cystoscopy at three months, then every six months for two years if negative and annually for ten years. Intermediate-risk high-grade Ta disease follows the high-risk schedule. [1]
  • For high- or very-high-risk disease, EAU suggests cystoscopy and cytology at three months and, if negative, every three months for two years, every six months until year five and annually lifelong. Add yearly long-term upper-tract CT urography. [1]
  • During follow-up, positive cytology without visible bladder tumour warrants mapping or photodynamic-guided biopsies and investigation of extravesical sites, including CT urography and prostatic-urethral biopsy. [1]

Limitations and use

  • This summary does not reproduce the complete risk-group calculation, surgical technique, all BCG-failure categories or management of BCG infection and systemic adverse effects.
  • Emerging bladder-preserving treatments and checkpoint combinations require individual eligibility review and current local approval/access checks; this source does not establish Indian approval.
  • Follow-up intervals are mostly weak recommendations. Intravesical agents, doses, preparation and procedural safeguards require complete protocols.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Non-muscle-invasive bladder cancer

    Selected recommendation material consulted

Clinical guideline

Publication details

Issuing organisation
EAU
Resource type
Clinical guideline · House clinical summary
Source setting
Europe

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Establish stage and obtain adequate tissue
  • Match risk prediction to the treatment population
  • Choose adjuvant therapy by recurrence and progression risk
  • Observe BCG exclusions and distinguish true unresponsiveness
  • Continue risk-adapted surveillance
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House